Posts Tagged ‘ eisai ’

Novel Once-Daily Epilepsy Treatment now Available in France

April 17, 2012
By

Hatfield, England (ots/PRNewswire) - Reimbursement granted for Zebinix(R) as adjunctive therapy for adults with partial-onset seizures Eisai Europe Limited announces the launch of Zebinix(R) (eslicarbazepine acetate) in France. Upon launch, this novel epilepsy drug will receive full reimbursements from the French health authorities. Once-daily eslicarbazepine acetate is indicated as an adjunctive (add-on) therapy for adults…

Read more »

Inovelon® (rufinamide) Drinkable Suspension Launches in Denmark

April 16, 2012
By

Hatfield, England (ots/PRNewswire) - Child-friendly formulation now available for the treatment of Lennox-Gastaut syndrome Eisai Europe Limited today announced the launch of Inovelon(R) (rufinamide) oral suspension in Denmark for adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut syndrome (LGS), in children four years and older. Many patients who receive the orphan drug rufinamide are children,…

Read more »

Inovelon®(Rufinamid) als Suspension erstmals in Europa erhältlich

March 15, 2012
By

Hatfield, England (ots/PRNewswire) - Patientenfreundliche Formulierung soll Behandlung des Lennox-Gastaut-Syndroms primr bei jungen Patienten in Deutschland erleichtern Eisai Europe Limited gab heute die Einfhrung von Inovelon(R) (Rufinamid) als orale Suspension in Deutschland bekannt. Die Suspension ist zur Zusatztherapie von Anfllen bei Lennox-Gastaut-Syndrom (LGS) ab vier Jahren zugelassen. Bei einem Grossteil der Patienten, die das Orphan…

Read more »